- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin, Pharmacokinetic sampling - rosuvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550
- Procedure · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 4,500
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Elastography, Multigated Acquisition Scan, Necitumumab, Osimertinib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 15
- States / cities
- Duarte, California • Palo Alto, California • Sacramento, California + 7 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Navlimetostat, Pumitamig
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Nivolumab, Ipilimumab, Paclitaxel
- Drug
- Lead sponsor
- Jeffrey Clarke
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- 45 Gray (Gy) regimen
- Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 6
- States / cities
- Greenwich, Connecticut • Guilford, Connecticut • Hamden, Connecticut + 3 more
- Conditions
- Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
- Interventions
- Stereotactic Body Radiation Therapy (SBRT)
- Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more
- Conditions
- Lung Cancer (Diagnosis), Osteochondroma, Spitz Nevus, Solid Cancers, Breast Cancer, Gastric (Stomach) Cancer, Colorectal (Colon or Rectal) Cancer, Sarcoma, Ovarian Adenocarcinoma, Uterine Adenocarcinoma, Endometrial Adenocarcinoma, Esophageal Adenocarcinoma, Head and Neck Cancer, Therapy-Related Acute Myeloid Leukemia, Therapy-Related MDS, Clonal Hematopoiesis of Indeterminate Potential (CHIP), Clonal Cytopenia of Undetermined Significance
- Interventions
- Samples
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cancer
- Interventions
- I-131-CLR1404
- Drug
- Lead sponsor
- Cellectar Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
- Interventions
- CDX-585
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Celebration, Florida • New York, New York + 1 more
- Conditions
- Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Malignant Melanoma, Esophageal Squamous Cell Carcinoma
- Interventions
- RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
- Biological · Drug
- Lead sponsor
- Rapa Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Cancer, Lung Cancer
- Interventions
- 18F-C-SNAT4, Positron emission tomography (PET)/Computed tomography (CT) Scan
- Drug · Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer
- Interventions
- Dovitinib
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Cetuximab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 8
- States / cities
- Aventura, Florida • Miami Beach, Florida • Chicago, Illinois + 4 more
- Conditions
- Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- tipifarnib, cisplatin, gemcitabine hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lung Cancer
- Interventions
- Celecoxib, Cisplatin, CPT-11, Concurrent Thoracic Radiation Therapy
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Neoplasms
- Interventions
- CI 1033
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Greenbrae, California • San Francisco, California + 30 more
- Conditions
- NSCLC
- Interventions
- REGN5093
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 8
- States / cities
- Orange, California • Washington D.C., District of Columbia • Tampa, Florida + 4 more
- Conditions
- Healthy, no Evidence of Disease, Lung Cancer
- Interventions
- proteomic profiling, biologic sample preservation procedure, laboratory biomarker analysis, bronchoscopy
- Genetic · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- crizotinib, pemetrexed disodium, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 167
- States / cities
- Sacramento, California • Aurora, Colorado • Colorado Springs, Colorado + 111 more
- Conditions
- Multiple Ground Glass Opacities (GGOs)
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 29
- States / cities
- San Diego, California • Stanford, California • Hartford, Connecticut + 18 more
- Conditions
- End of Life, Cancer
- Interventions
- Receive technology-based supportive cancer care, Receive redesigned team-based supportive cancer care
- Other · Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Duarte, California + 11 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Fujirebio Diagnostics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Eastpointe, Michigan • Bridgeton, Missouri • Saint Joseph, Missouri + 1 more
- Conditions
- Lung Cancer
- Interventions
- marimastat
- Drug
- Lead sponsor
- ILEX Oncology Services, Incorporated
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2004
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Greenbrae, California + 38 more